Polaryx Therapeutics, Inc. Common Stock

NASDAQ:PLYX

Biotechnology

Healthcare
$1.61 -0.87%

-$0.02 today

Market cap
$80.25M
Beta
0.00
P/E (TTM)
-16.7
EPS (TTM)
-$0.14
52W Low $2.01High $48.91

Volume 0.02M

Average 0.34M

PLYX Total Equity

Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.

Polaryx Therapeutics, Inc. Common StockNASDAQ: PLYX

Total Equity · Q1 FY2026 · quarter ended Mar 2026

Total equity falls 41.5% from a year ago

Total equity stood at $2.49M at the end of Q1 FY2026, down 41.5% from a year earlier and down 45.5% from the prior quarter.

Context

  • Total equity amounted to 71.0% of total assets at the end of Q1 FY2026, down 24.8 pp from a year earlier.
  • Total equity increased in 1 of the last 2 fiscal years.

What to watch

Whether total equity keeps falling in the next quarterly balance sheet after a -41.5% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.49M-45.5% QoQ
Last fiscal yearDec 2025
$4.57M-3.1% YoY
Year agoMar 2025
$4.25M-41.5% since
Total Equity past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-41.5%——
1 year-3.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Total Equity history

USD · from the balance sheet

Latest · FY2025
4.57M USD
Year-over-year change
-3.1%
2-year CAGR
+89.1%

Total Equity vs competitors

How PLYX compares with its peers on the latest reported figures

  • PLYX's Mar 2026 total equity of $2.49M is the 7th highest of the 8 companies compared; the peer median is $81.76M.
  • Its year-over-year change of -41.5% is the lowest of 8, against a peer median of +11.5%.
  • Total equity amounts to 71.0% of total assets for PLYX, versus a peer median of 78.1%.
PLYX Competitors Peer median
Total Equity for PLYX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
JBIOJade Biosciences, Inc.Mar 2026$296.46M +295.0%+37.9%92.8%
LYELLyell Immunopharma, Inc.Mar 2026$273.67M -18.7%-33.2%78.1%
CBIOCrescent Biopharma, Inc.Mar 2026$183.85M +5346.9%+67.8%92.3%
ANTXAN2 Therapeutics, Inc.Mar 2026$81.76M +11.5%-17.8%93.4%
KLRSKalaris Therapeutics IncMar 2026$68.56M +7.3%—62.4%
PTHSPelthos Therapeutics Inc.Mar 2026$35.1M +936.6%—24.1%
PLYXPolaryx Therapeutics, Inc. Common StockMar 2026$2.49M -41.5%—71.0%
FHTXFoghorn Therapeutics Inc.Mar 2026-$76.41M -23.9%—34.4%
Peer median (excluding PLYX) $81.76M+11.5%+10.1%78.1%

Competitors are the stored peer set for PLYX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Polaryx Therapeutics, Inc. Common Stock

NASDAQ:PLYX

Intrinsic Alpha fair value

Locked

Current Price

$1.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.